American Society of Hematology

American Society of Hematology
The American Society of Hematology’s 59th Annual Meeting and Exposition will be held December 9-12, 2017, in Atlanta, Georgia. Professionals from around the world will present and discuss their research and latest developments in malignant and non-malignant hematology. Sign up for our daily e-mail blasts , and check back here during the conference for our complete meeting coverage.
December 12, 2017
Stephen Schuster, MD, of the Perelman School of Medicine, provides a summary of results seen with CAR T treatments in leukemia, lymphoma, and myeloma.
December 12, 2017
Including the modified brentuximab antibody in the treatment regimen improved modified progression-free survival by 5%, although the rates of neutropenia and infections were higher in patients administered the brentuximab-containing regimen.
December 12, 2017
Adolescents and young adults with acute lymphoblastic leukemia (ALL) tend to have worse outcomes than children with ALL, and new research published at the 59th American Society of Hematology Annual Meeting delved into the reasons why, explained Julie A. Wolfson, MD, of the University of Alabama at Birmingham School of Medicine.
December 12, 2017
Right now is a critical time for the healthcare industry to evaluate how patients are financially burdened by novel treatments that can provide tremendous outcomes, said Joshua R. Richter, MD, of the John Theurer Cancer Center.
December 11, 2017
A much-anticipated session on the second day of the 59th Annual Meeting and Exposition of the American Society of Hematology provided long-term updates on trials evaluating 2 chimeric antigen receptor-T (CAR T) treatments: tisagenlecleucel or CTL019 (Kymriah) for the treatment of adult relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and axicabtagene ciloleucel (Yescarta) evaluated in patients with refractory aggressive non-Hodgkin lymphoma.
December 11, 2017
Patients with blood cancers tend to use hospice care services less frequently overall than patients with solid tumors. While there has been an increase in hospice care use in patients with blood cancers, there has been a failure to increase hospice use meaningfully, according to Thomas LeBlanc, MD, of the Duke Cancer Institute.
December 11, 2017
Providing outpatient hematopoietic stem cell transplant (HSCT) when patients are eligible is a good way to reduce costs, without impacting outcomes, explained Nina Shah, MD, associate professor, University of California, San Francisco, School of Medicine.
December 11, 2017
Clonal hematopoiesis and selection pressures associated with aging can together lead to the development of neoplasms. Two hematologists presented US and European updates on the potential to develop a predictive model, and an appropriate intervention, in these individuals.
December 11, 2017
Two abstracts at the 59th Annual Meeting of the American Society of Hematology in Atlanta, Georgia found that CTL019 shows promising potential in providing significant benefit and cost effectiveness for pediatric and young adult patients with B-cell acute lymphoblastic leukemia in both the United States and the United Kingdom.
 
December 11, 2017
Is transfusion dependence a barrier to hospice utilization among older patients with leukemia who are enrolled in Medicare?
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome to the new and improved AJMC.com, the premier managed markets network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!